Right ventricular (RV) function and its adaptation to increased afterload [RV–pulmonary
arterial (PA) coupling] are crucial in various types of pulmonary hypertension, determining …

Cardiovascular diseases have become a major clinical burden globally. Heart failure is one
of the diseases that commonly emanates from progressive uncontrolled hypertension. This …

Background Sacubitril/valsartan (S/V) demonstrated significant effects in improving left
ventricular performance and remodeling in patients with heart failure with reduced ejection …

Background: Sacubitril/valsartan was demonstrated to reduce hospitalization rate and
mortality in patients with heart failure with reduced ejection fraction. Data on the effects of …

Background: Transcatheter mitral valve repair (TMVR) is an effective therapy for high-risk
patients with severe mitral regurgitation (MR) but heart failure (HF) readmissions and death …

Aims Optimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic
heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation …

Sacubitril/Valsartan (S/V) carries potential anti-remodeling properties, however long-term
effects and biventricular adaptive response are poorly described. 76 HFrEF patients who …

Aims The angiotensin receptor‐neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val)
demonstrated to be superior to enalapril in reducing hospitalizations, cardiovascular and all …

Background This study aimed to evaluate the effect of sacubitril valsartan (SV) on heart
failure (HF) hospitalization and cardiovascular mortality in patients on hemodialysis with HF …

The purpose of this study was to investigate the effects of sacubitril/valsartan on right
ventricular (RV) function in patients with pulmonary hypertension (PH) due to heart failure …